Treatment with selective early-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has demonstrated high efficacy in patients with lung cancer harboring activating EGFR mutations. This evidence concerns the gene EGFR and lung cancer.